63 completed, 12 unknown, 7 withdrawn, 6 terminated. 91 Phase 2, 27 Phase 1, 15 Phase 3.
Follow Lucentis: new trials by email Literature Review of Lucentis trials Research Report on Lucentis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of 2 Doses of Remigromig (EYE103) Compared With Ranibizumab (0.5 mg) in Participants With DME Remigromig, Ranibizumab - Diabetic Macular Edema (DME) | Phase 2 / Phase 3 | Active not recruiting | EyeBiotech Ltd. | 1054 | 2025-04-16 | 2026-10-30 |
| A Study to Evaluate the Efficacy and Safety of 2 Doses of Remigromig (EYE103) Compared With Ranibizumab (0.5 mg) in Participants With DME Ranibizumab, Remigromig - Diabetic Macular Edema (DME) | Phase 2 / Phase 3 | Active not recruiting | EyeBiotech Ltd. | 984 | 2024-08-07 | 2026-11-10 |
| A Study to Investigate Vamikibart (RO7200220) in Diabetic Macular Edema Vamikibart, Ranibizumab, Sham Procedure - Diabetic Macular Edema | Phase 2 | Completed | Hoffmann-La Roche | 394 | 2021-12-31 | 2026-05-11 |
| Long-Term Follow-Up Study of RGX-314 Administered in the Suprachoroidal Space for Participants With nAMD Standard of Care, Ranibizumab - Neovascular Age-Related Macular Degeneration (nAMD) | Phase 2 | Enrolling by invitation | AbbVie | 116 | 2021-12-20 | 2026-08-05 |
| A Study to Investigate Vamikibart (RO7200220) in Combination With Ranibizumab in Diabetic Macular Edema Vamikibart, Ranibizumab, Sham Procedure - Diabetic Macular Edema | Phase 2 | Completed | Hoffmann-La Roche | 187 | 2021-12-17 | 2025-10-16 |
| A Study to Evaluate the Efficacy and Safety of MW02 in the Treatment of nAMD MW02, Lucentis - Wet Age-related Macular Degeneration | Phase 2 / Phase 3 | Unknown | Mabwell (Shanghai) Bioscience Co., Ltd. | 433 | 2021-05-07 | 2022-03-28 |
| 601 Versus Ranibizumab in Patients With Branch Retinal Vein Occlusion (BRVO) 601 1.25mg, Ranibizuman 0.5 mg - Branch Retinal Vein Occlusion | Phase 2 | Completed | Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. | 60 | 2021-01-28 | 2025-06-27 |
| 601 Versus Ranibizumab in Patients With Central Retinal Vein Occlusion (CRVO) 601 1.25mg, Ranibizuman 0.5 mg - Central Retinal Vein Occlusion | Phase 2 | Completed | Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. | 60 | 2021-01-27 | 2025-06-27 |
| Combined Ranibizumab and Iluvien for Diabetic Macular Oedema Iluvien 0.19 MG Drug Implant, Ranibizumab Injection [Lucentis], Sham Intravitreal Injection - Diabetic Macular Edema, Diabetes | Phase 2 / Phase 3 | Withdrawn | Imperial College London | 2019-09-01 | 2023-10-02 | |
| Multiple Dose Safety and Efficacy of LKA651 in Patients With Diabetic Macular Edema LKA651, Lucentis - Diabetic Macular Edema | Phase 2 | Completed | Novartis Pharmaceuticals | 91 | 2019-05-24 | 2024-06-20 |
| Evaluation of the Safety and Efficacy of ALS-L1023 Administered in Combination With Ranibizumab in Patients With Wet-AMD ALS-L1023, Ranibizumab, Placebo - Age-Related Macular Degeneration | Phase 2 | Completed | AngioLab, Inc. | 126 | 2018-12-07 | 2022-08-11 |
| A Dose Ranging Study of OPT-302 With Ranibizumab in Neovascular (Wet) AMD OPT-302, ranibizumab, sham intravitreal injection - Neovascular Age-related Macular Degeneration | Phase 2 | Completed | Opthea Limited | 366 | 2017-11-06 | 2021-01-12 |
| ZIMURA in Combination With LUCENTIS in Patients With Neovascular Age Related Macular Degeneration (NVAMD) Avacincaptad Pegol, Lucentis - Neovascular Age-related Macular Degeneration | Phase 2 | Completed | Ophthotech Corporation | 64 | 2017-10-11 | 2025-06-10 |
| Efficacy of Biweekly Ranibizumab (0.5 mg) for Exudative Macular Degeneration Retinal Edema Refractory to Anti-VEGF Ranibizumab Injection [Lucentis] - Exudative Age Related Macular Degeneration | Phase 2 | Completed | Southeast Clinical Research Associates, LLC | 20 | 2017-10-01 | 2020-10-22 |
| Study Assessing the Efficacy and Safety of Intravitreal Injections of DE-122 in Combination With Lucentis® Compared to Lucentis® Monotherapy in Wet Age-related Macular Degeneration Subjects 2.0 mg DE-122 Injectable Solution + Lucentis, 4.0 mg DE-122 Injectable Solution + Lucentis, Lucentis - Age-Related Macular Degeneration | Phase 2 | Completed | Santen Inc. | 76 | 2017-07-05 | 2021-07-13 |
| Safety Study of Zimura in Combination With Anti-VEGF Therapy in Patients With Neovascular AMD Avacincaptad Pegol, Avastin, Lucentis - Neovascular Age-Related Macular Degeneration | Phase 2 | Terminated | IVERIC bio, Inc. | 1 | 2016-10-20 | 2025-03-13 |
| A Study of Faricimab (RO6867461) in Participants With Center-Involving Diabetic Macular Edema Faricimab, Ranibizumab - Diabetic Macular Edema | Phase 2 | Completed | Hoffmann-La Roche | 229 | 2016-04-27 | 2020-09-25 |
| A Proof-of-Concept Study of Faricimab (RO6867461) in Participants With Choroidal Neovascularization (CNV) Secondary to Age-Related Macular Degeneration (AMD) Faricimab, Ranibizumab, Sham Procedure - Choroidal Neovascularization | Phase 2 | Completed | Hoffmann-La Roche | 273 | 2015-08-11 | 2020-11-12 |
| The Effect of Intravitreal Ranibizumab on Visual Acuity and Hard Exudate Resolution in the Treatment of Diabetic Macular Edema With Center Involved Edema and Lipid Exudates ranibizumab 0.3mg - Diabetic Macular Edema, Hard Lipid Exudates | Phase 1 / Phase 2 | Completed | South Coast Retina Center; Carson, McBeath, Boswell, Inc. | 25 | 2015-08-01 | 2021-07-08 |
| Analysis of Aqueous and Vitreous Humor Ranibizumab, No Ranibizumab - Proliferative Diabetic Retinopathy, Macular Degeneration | Phase 2 | Unknown | California Retina Consultants | 45 | 2015-07-01 | 2017-03-01 |
Showing 20 of 91. Sign in to see all of them.
Macular Degeneration (24) · Macular Edema (12) · Choroidal Neovascularization (9) · Retinal Vein Occlusion (9) · Diabetic Retinopathy (8) · Diabetes Mellitus (5) · Polypoidal Choroidal Vasculopathy (5) · Edema (4) · Vision Disorders (4) · Wet Macular Degeneration (4) · Retinal Diseases (3) · Angioid Streaks (2) · Glaucoma (2) · Glaucoma, Neovascular (2) · Pseudoxanthoma Elasticum (2)
Hoffmann-La Roche (4) · University of Sao Paulo (4) · California Retina Consultants (3) · Ophthotech Corporation (3) · Southeast Retina Center, Georgia (3) · Arshad Khanani (2) · David M. Brown, M.D. (2) · EyeBiotech Ltd. (2) · Jaeb Center for Health Research (2) · Johns Hopkins University (2) · Novartis (2) · Quark Pharmaceuticals (2) · Santen Inc. (2) · Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. (2) · University Hospital, Bonn (2)
United States (60) · Germany (7) · Spain (7) · United Kingdom (7) · Canada (6) · Poland (6) · Israel (5) · Puerto Rico (5) · South Korea (5) · Argentina (4) · Austria (4) · Brazil (4) · China (4) · Czechia (4) · Hungary (4)
Charles Miller, MD PhD (2) · David M Brown, MD (2) · Dennis M. Marcus, M.D. (2) · Hendrik PN Scholl, MD, MA (2) · Reinier O Schlingemann, MD, PhD (2) · Robert L Avery, MD (2) · Rodrigo Jorge, MD, PhD (2) · Abdhish Bhavsar, MD (1) · Adam R. Glassman, MS (1) · Albert T Vitale, MD (1) · Allen Ho, MD (1) · Amy C Schefler, MD (1) · Andreas Stahl, MD (1) · Andrew Strong, Ph.D (1)
PMID 30957581, PMID 17367957, PMID 18214740, PMID 20163368, PMID 20417925, PMID 20856107, PMID 20877651, PMID 20885313, PMID 21232078, PMID 21334595, PMID 21681707, PMID 21704964, PMID 21742303, PMID 21915047, PMID 21955635, PMID 22081150, PMID 22357391, PMID 22424834, PMID 22457045, PMID 22882007, PMID 22990319, PMID 23187164, PMID 23370902, PMID 23486999, PMID 23544200, PMID 23777441, PMID 23795985, PMID 24026871, PMID 24326333, PMID 24335454, PMID 24923076, PMID 24923077, PMID 24967201, PMID 24982728, PMID 25001321, PMID 25019269, PMID 25079064, PMID 25390730, PMID 25633882, PMID 27836430, PMID 27842163, PMID 29127949, PMID 29309486, PMID 29729809, PMID 30905643, PMID 31388454, PMID 32303499, PMID 32729888, PMID 34201045, PMID 34463842
2018 (1), 2025 (1), U10EY014231 (1), U10EY018817 (1)